| 摘要 |
Disclosed is a composition for treating memory disorders and cognitive decline, e.g., age-related cognitive decline, in a primate which includes a therapeutically effective amount of an alpha-2 agonist having a high affinity for the alpha-2I subtype, e.g., guanfacine and guanabenz or a nontoxic, pharmaceutically acceptable salt thereof. Particularly preferred is the use of alpha-2I selective agonists such as guanfacine. |
